ALI HEALTH (00241) rose nearly 3%, reaching HK$6.1 by the time of writing, with a trading volume of HK$499 million. The increase comes amid reports of a rising flu season, leading to heightened demand for related medications on ALI HEALTH's platform.

Data from ALI HEALTH shows that over the past two weeks (November 10–23), both interest and purchases of flu-related medications have surged significantly. Antiviral drug purchases increased by over 500% month-on-month, with baloxavir marboxil seeing the most notable growth—up more than 600%. Antiviral oral solutions also saw a 50% rise in purchases, reflecting stronger public awareness of flu prevention.

Nationwide, flu activity has accelerated since November, with Beijing entering a peak period for respiratory infections. Analysts at Everbright Securities noted that since the start of autumn 2025, declining temperatures have contributed to a clear uptick in flu cases. The current surge in infections may drive greater public and market attention, boosting demand for flu prevention, treatment, and testing products.

The firm highlighted that Q4 2025 marks the peak season for cold and flu medications, with sales and shipments likely to exceed market expectations given the current upward trend in flu cases.